medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2008, Number 1

<< Back Next >>

Rev Mex Angiol 2008; 36 (1)

Utilidad del tratamiento coadyuvante con glicofosfopeptical (GPP) como inmunomodulador en lesiones de los pies de pacientes diabéticos

Ruiz MH, Serrano LJA, Revilla CH, Meza VMA, González HJA, Parra PR, Hernández LD, Sarmiento HAP, Albor OL, Peralta AUA

Language: Spanish
References: 37
Page: 7-13
PDF size: 257.41 Kb.


ABSTRACT

Objective: To dete1mine the effect of GPP in the treatment of patients with diabetic foot.
Backgrortnd: According to the Ministry of Health in 1993, diabetes was found in the third place as one of the main causes of death in Mexico, with a prevalence of 10.7% according to the Diabetes Mexican Federation. Diabetic foot ulcers are a complication that contributes to the formation of serious infections and increases the risk of amputation. There is evidence that shows the presence of an immune dysfunction associated with diabetes. Glycophosphopeptical is a drug extracted from Candida utilis; its activity favors the immune response. lt has also been shown that it stimulates phagocytosis and favors the clinical evolution in several groups of patients, generating an improvement in the clinical evolution of patients with immune system damage and providing greater resistance to infection.
Metods: An open, longitudinal, prospective, multi center trial was carried out. Thirty five patients with diabetic foot grade I V in the Wagner classification who received GPP 1 g every 8 hours for 6 weeks were studied.
Results: lt has found an improvement in the immune parameters of patients, including increased phagocyte activity, and cytocide capacity depending on the generation of oxygen radicals.
Conclusions: The use of glycophosphopeptical substantially improves the immunologic parameters of diabetic patients with lower limb lesions; improving the patient's immune response to reduce the incidence of infections and improving the scaring process.


REFERENCES

  1. l. Secretaría de Salud. Proyecto de modificación a la norma oficial mexicana NOM 015 SSA2 1994 para la prevención, tratamiento y control de la diabetes. Reu Med IMSS 2000; 38(6): 477 95.

  2. Vázquez MJ, Gómez DH, Fernández CS. Diabetes mellitus en población adulta del IMSS. Resultados de la Encuesta Nacional de Salud 2000. Reu Med IMSS 2006; 44(1): 13 26.

  3. Guzmán JN, Madrigal BE. Revisión de las características clínicas, metabólicas y genéticas de la diabetes mellitus. Bioquimia 2003; 28(2): 14 23.

  4. Federación Mexicana de Diabetes A.C. Diabetes en núme ros [en línea] México. [Fecha de consulta: 30 de julio de 2007] Disponible en: http://www.fmdiabetes.com/www/dia betes/dnumeros.asp#Mexico

  5. López AS, López AF. Diabetes mellitus y lesiones del pie. Salud Pública Mex 1998; 40(3): 281 93.

  6. Guyton PG, Saltzman LC. The Diabetic Foot: Basic Mechanis ms ofDisease. J Bone Joint Surg Am 2001; 83(7): 1083 96.

  7. López AS, López AF. Diabetes mellitus y lesiones del pie. Salud Pública Mex 1998; 40(3): 281 93.

  8. Guyton PG, Saltzman LC. The Diabetic Foot: Basic Mechanis ms ofDisease. J Bone Joint Surg Am 2001; 83(7): 1083 96.

  9. Cacciatori V, Defiera A, Bellavere F, Bongiovanni LG, Tea tini F, Gemma ML, et al. Comparative assessment ofperi phe.ral aympa thetic function by poatur-al vaaooon.atriction arteriolar l'@tlex and aympethetic akin reapon3e in NlDDM pa tie.nta . . 4mJ M«f 1997; 102(4): 365 70.

  10. 8 . Ubbin.k DT, Kitalaar PJ, Tordoir J H, Ren e.ovut RS, Jac:obe MJ . Skin microci rtulation in diabetic a nd no ndiabetic pa t ie.ltts a t diff e.re.•lt atagea of lowe.r limb iachaemia. Eur J Va8cSur-g 1993; 7(6): 656 9.

  11. Jo"'eoener EP, Ki ng GL. Va;:scular dyafunction in diabetes me llitw. 7'11e Lan«t 1997; 350(Suppl 1): Sl9 813.

  12. Hein2:elruann M, Scott M, Lam T. Factor-a prediapoaing to bacteria! inva;:sion a nd üt fed.ion . Ameii:an Journal o{ Sur gey 0002; 183: 179 90.

  13. Caputo GM, Joahi N, Weite.kamp MR Jo~oot infec tioru~ in patienta with diabetes. Am Fam Physii:ian 1997: 5~1): 195 202.

  14. Eliopouloa G. lnfections in diabetes meUi.tua lnfect Dis Clin N011.h .4m 1995; 9.

  15. E ngelich G, Vright G, Hal"tahon LK. At:qui red diaordera of phagoc:yte function complicating medica! and surgical ill n esa. ClinU:al infecriou8disealltt. 2001; 33(12): 2010 9.

  16. Repine JE, Clawson ce, Goeh Jo"'C. Bactericidal fu:nction of n eutrophil3 from pa tie n ta witb acute bacteria( i nfections and from diabetiea. J ln(ect Dis 1980; 142:869 75.

  17. Alexiewic:z JM, Kuruar D, Smogorzewslri M, et aL Polyruor phonuclea.r leukocytea Ut oon in.auli n depo:mdent diabetes mellitw: a bnormalitiea i n metabolism and fw1ction. Ann lntem Med 1995; 123: 919 24.

  18. Rayñ eld EJ, Ault MJ, Keuach GT, et aL lnfection and dia bet:.e-3: tbe caae for glut:lOSe contr-oL .4m J .Mt:d 1982: 72: 439 50.

  19. Pompoaelli JJ, Baxter JK 3d, Babineau T, et aL Early poatope.rative glucoae oontrol predicta noaoooruial infection rate iu diabe tic patienta. JPEN J Pann.tu Entero/ Nutr 1998; 22: 77 81.

  20. Bravi MC, PietrangeH P, Lau l'@nti O, et al. Polyol p.athway activation and glutathione redox .status in non i ru~ulin de pe.ndent diabetic pa tienta. MetaboliiJm 1997; 46: 1194. 8.

  21. 19 . Sá nc h et- GJ . Diabetes: Di3 minución de complic acio nea y ot ros retos. Diabet Hoy Med Sal 2006; 7( 5). ! Cit ada 2006 ltov 151 http://ir:nb iorued.com/1/ 1/ art iculoa .php?id reviat a=89&id ejerupla.r-=3973

  22. Real CJT, Valla M, Ba.aan ta AML, Ampudia BJo~, A3.ca;:so GJJo~, Catmena RR. & tudio de factores aaoc:iadoa con am putación, en pacientee; diabéticos oon ulceración eo pie . . 411 Med lnuma 2001; 18(2): 59 62.

  23. Levin ME. Prew.ntig amputation in Ute petient with di abe tea. Dillbete8 Ca~ 1995; 18(10): 1383 9-t.

  24. Wagner FW Jr. T he diabetic foot. Orthop«iiCIJ 1987; 10( 1): 163 72.

  25. Gough A, Cla pperto11 M, Rolando N, Jo'"'oater AV, Phil pott Howa.rd J, Edmonda ME. Ran domized placebocontroUed t ri al o f gr-anuloc::yte colony a timula ti ng factor in diabe tic foot infection . 'l'he Lancd. 1007; 350(9081): 855 85.

  26. Rivera LR, Cárdenaa CR, &ta.rtí nu GG, Mez.a ce. Efec to del AM3 en la granuloc::itopen ia en pacientes pediátri coa con tumores~ sólidos. Can«l'olOJ!la 1990; 36(2): 1027 32.

  27. Bourlon R, De loa Ríoa M, Juárez P, Olguín E, De la Gana J . Reporte preliminar de la uti lidad de un nuevo modifica dor de la n=s pueata biológica (MRB) AM3• en el tratamieo to de la hepeti ti3 crónica B. Comp ln P Clin Lal.4m 1992; 12(1).

  28. De la Gana JS, Raruíl'@l. MTU, Ramírez ~1M, Atam NL. Evaluación de lnmunoferon (AM3) eo la recuperación de la depleción medular en pacie ntea con cáncer de mama so me tidaa a q uimioterapia. Reu del /NC 1987; 33(ol): 453 57.

  29. Sánchet.PA, Carda MJ A, Schamann AT. Valoración <:lú1iea de un ruod ü icador de la re-a pueata biológica, AM3, en el tra tami ento de la patología reapi.ratoria infecciosa infa ntiL .41/ergol Et lmmunopathol1992; 20(1): 35 9.

  30. Wi.achnik A. P·rofil axia con un nuevo modificador de la rea puesta biológica en l a;:s bro1tconeumopatíaa crónicas. Far macourapia 1986; 3(4): <111257 4..5/261.

  31. Ollero NT, Outiéri'@Z RM. Valoración clín ica de i11mu:nofe ron en el tratamien to de la bronq uitis cr611iea. Geriatrihl 198<1; 3.

  32. Arredondo A, Zúftiga A. Economic con.aequence;~ o f epi de miological chal"tgea in diabetes in ruiddle il)come CIOW)triea: the Mexican case. DiabeU& Can 2004; 27( 1): 104 9.

  33. Arredondo A. Jol.nancial requireme1tta for h eal tb servicea deman dil for diabetes and hy pertenaion i n Mexico: 0001 2003.Rev lnL't!llt C/in2001; 53(5): 4.22 9.

  34. Villarl'@al Ríos E, SalUUta &tartínez AM, MediJUt Jáu l'f!>gui A, Gana Elizondo ME, Ndne.z. Rocha G, Chuy Dfa.z. ER. 1'he coat of diabetes mellitua and ita imp.ac:t on b ealtb a pen ding in Mexico. Arch MedRe& 2000; 31(5): 511 4.

  35. Raacón Pacheco RA, Santillana M acedo MA, Romero Arre dondo ME, Rivera lcedo BM, Romero Cancio J A, Cota Rembau Al. Siatema de vigilan cia epidemiológica para el pacien te diabético; el u ao de tecnología computacional en la calidad de la atención médica. Salud Pública Mer2000; <12: 324 32.

  36. 34.. Alpú.a.t SM, Sotomayor GA, Cutro RMA, Zárate AA, M a dt-a.z.o M. Diabetea Mellitua, P·rioridad huti tucion al.. Reu Mid JMSS 1998: 36(1), 1 2.

  37. Amato D, Persao11 U, Lantin M, et aL The coat of i llnesa of patien ta with diabetic foot u lcers. D·U:Jbetes 1999; (Suppl): Ab.a tract #829.




2020     |     www.medigraphic.com